RVNC: Revance Therapeutics, Inc. Stock

by  •  • Comments Off on RVNC: Revance Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 382.00
Enterprise Value ($M) 754.60
Book Value ($M) -163.03
Book Value / Share -1.55
Price / Book -2.34
NCAV ($M) -294.91
NCAV / Share -2.81
Price / NCAV -1.30

Profitability (mra)
Return on Invested Capital (ROIC) -0.58
Return on Assets (ROA) -0.39
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 3.05
Current Ratio 4.12

Balance Sheet (mrq) ($M)
Current Assets 329.69
Assets 461.56
Liabilities 624.59
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
1 day ago 13D/A Teoxane SA
01-10 13G Beryl Capital Management LLC
10-31 13G/A Franklin Resources Inc
10-23 13G/A GIC Private Ltd 0.00 -100.00
10-07 13G/A Capital World Investors 0.00 -100.00
04-09 13G/A Jpmorgan Chase & Co 2.60 -41.77
02-14 13G/A Antara Capital LP 0.00 -100.00
02-14 13G/A Palo Alto Investors LP 5.96 -0.88
02-13 13G/A Vanguard Group Inc 5.77 12.75
02-13 13G/A Polar Capital Holdings Plc 3.60 -34.64
2024-01-25 13G/A BlackRock, Inc. 8.50 5.38

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P
2024-02-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PUR

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-31 369,132 3,488,665 10.58
2025-01-30 708,562 7,346,689 9.64
2025-01-29 101,775 884,393 11.51
2025-01-28 122,413 1,576,200 7.77
2025-01-27 102,226 1,306,516 7.82

(click for more detail)

Similar Companies
RLAY – Relay Therapeutics, Inc. RNA – Avidity Biosciences, Inc.
RNAC – Cartesian Therapeutics, Inc. RYTM – Rhythm Pharmaceuticals, Inc.
SAGE – Sage Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io